People suffering with chronic obstructive pulmonary disease (COPD) could soon receive a treatment, following positive trials of a drug comprising tiotropium and olodateral.
The TONADO study on tiotropium and olodateral (Respimat) looked at the experiences of more than 5,000 people living with COPD and found the drug provided increased lung function and improved quality of life compared to either compound alone.
The results, presented at this year’s European Respiratory Society International Congress 2014 in Munich, verified similar results presented in the VIVACITO study presented earlier this year.
Currently tiotropium (Spiriva) is the most prescribed treatment for COPD. Olodateral was specifically designed by Boehringer Ingelheim as a combination partner to tiotropium to provide added benefit for patients with COPD. Olodaterol monotherapy has received approval for the maintenance treatment of COPD in over 30 countries and is marketed under the brand name Striverdi Respimat in the UK.
“Spiriva® has been a cornerstone of maintenance therapy in COPD since its launch 12 years ago, providing benefit to millions of patients worldwide” said Dr Charles de Wet, Medical Director, UK and Ireland at Boehringer Ingelheim. “It is important however that we continually strive to expand treatment options for patients, so we are delighted to present data illustrating additional lung function and quality of life benefits with tiotropium + olodaterol Respimat® fixed dose combination therapy.”